Human studies firmly established an increased NR2F6 expression in various cancer types such as leukemia [41,56], colon carcinoma [39], cervical cancer [42], ovarian cancer [43,44], breast cancer [45,46,47,48,49,50,51,52,53,54,55,56,57], lung cancer [45,58] and hepatocellular cancer [38], suggesting that NR2F6 might be a prognostic marker. Here, NR2F6 is linked to ovarian carcinoma.